| pubmed-article:2387385 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2387385 | lifeskim:mentions | umls-concept:C0018796 | lld:lifeskim |
| pubmed-article:2387385 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:2387385 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2387385 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:2387385 | lifeskim:mentions | umls-concept:C0053939 | lld:lifeskim |
| pubmed-article:2387385 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2387385 | pubmed:dateCreated | 1990-9-24 | lld:pubmed |
| pubmed-article:2387385 | pubmed:abstractText | In 10 patients with frequent ventricular extrasystoles there were studied the antiarrhythmic effectiveness and side effects of a new drug bonnecor at a single intravenous administration in doses from 15 to 60 mg (0.17-0.91 mg/kg). It was found that the drug exerted the antiarrhythmic effect at dosages of over 0.4 mg/kg and side effects and toxic effects occurred at dosages of over 0.7 mg/kg. The optimal dose for a single intravenous administration was regarded to be the dose of 0.6 mg/kg. The mechanisms of action of bonnecor were studied during intracardiac electrophysiological investigation. The drug was shown to suppress the conduction of excitation along the atrioventricular node, the His-Purkinje system, the ventricular myocardium and the abnormal pathways of conduction. Thus, bonnecor may be referred to as an agent of class I according to the classification of Vaughan Williams. When administered intravenously (0.6 mg/kg) bonnecor was found to interrupt and prevent the recurrent development of atrioventricular tachycardia and also supraventricular tachycardias at the presence of the abnormal pathways of conduction. | lld:pubmed |
| pubmed-article:2387385 | pubmed:language | rus | lld:pubmed |
| pubmed-article:2387385 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2387385 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2387385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2387385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2387385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2387385 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2387385 | pubmed:issn | 0014-8318 | lld:pubmed |
| pubmed-article:2387385 | pubmed:author | pubmed-author:GolitsynS PSP | lld:pubmed |
| pubmed-article:2387385 | pubmed:author | pubmed-author:SokolovS FSF | lld:pubmed |
| pubmed-article:2387385 | pubmed:author | pubmed-author:BankuzovV AVA | lld:pubmed |
| pubmed-article:2387385 | pubmed:author | pubmed-author:MalakhovV IVI | lld:pubmed |
| pubmed-article:2387385 | pubmed:author | pubmed-author:KoltunovaM... | lld:pubmed |
| pubmed-article:2387385 | pubmed:author | pubmed-author:GolitsynL SLS | lld:pubmed |
| pubmed-article:2387385 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2387385 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:2387385 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2387385 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2387385 | pubmed:pagination | 57-60 | lld:pubmed |
| pubmed-article:2387385 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:meshHeading | pubmed-meshheading:2387385-... | lld:pubmed |
| pubmed-article:2387385 | pubmed:articleTitle | [The anti-arrhythmia activity and effect on the heart conduction system of the new anti-arrhythmia preparation bonnecor]. | lld:pubmed |
| pubmed-article:2387385 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2387385 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2387385 | pubmed:publicationType | English Abstract | lld:pubmed |
